Using tissue microarray data of stage-I NSCLC samples from 394 patients, Lim et al. [189] found that the lower expression of RIPK3 and PELI1 with a combination of higher p53 expression, a key DNA damage response factor, is linked with poor survival of stage-I NSCLC patients. This evidence concerns the gene PELI1 and non-small cell lung carcinoma.